The Pat Kenny Show The appetite for weight-loss drugs has been insatiable
Nov 13, 2025
Professor Luke O'Neill, a leading biochemist from Trinity College Dublin, dives into the booming market of GLP-1 weight-loss drugs, projected to hit $54 billion in 2024. He discusses the rapid demand growth and the safety concerns, particularly muscle loss associated with these treatments. O'Neill contrasts oral and injectable formulations, highlighting their effectiveness. Additionally, he sheds light on the broader impacts these drugs could have beyond weight loss, including potential benefits for addiction and heart health.
AI Snips
Chapters
Transcript
Episode notes
Rapid Expansion Of GLP-1 Market
- GLP-1 weight-loss drugs have rapidly become a major market presence since their recent introduction.
- Multiple new versions and combinations are in development to improve efficacy and reduce side effects.
Muscle Loss Is A Noted Side Effect
- Long-term effects of GLP-1 drugs remain incompletely known despite years of use.
- One clear downside is concurrent muscle loss, which newer combinations aim to prevent.
Oral Pills Could Replace Injections
- Oral GLP-1 formulations are in trials and could replace injections for convenience.
- Early oral versions show slightly lower weight-loss percentages than injectables but could broaden uptake.